<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149108</url>
  </required_header>
  <id_info>
    <org_study_id>1199.52</org_study_id>
    <secondary_id>2012-000095-42</secondary_id>
    <nct_id>NCT02149108</nct_id>
  </id_info>
  <brief_title>Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)</brief_title>
  <official_title>A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients
      with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard
      chemotherapy and biological agents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2014</start_date>
  <completion_date type="Actual">August 25, 2016</completion_date>
  <primary_completion_date type="Actual">May 13, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) by Central Review Assessment</measure>
    <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
    <description>PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan−Meier curve for each treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
    <description>OS was defined as the time from randomisation to the time of death from any cause.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan−Meier curve for each treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment</measure>
    <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
    <description>Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment</measure>
    <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
    <description>Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">768</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Nintedanib (BIBF 1120) + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + BSC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib (BIBF 1120)</intervention_name>
    <arm_group_label>Nintedanib (BIBF 1120) + BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSC</intervention_name>
    <arm_group_label>Placebo + BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSC</intervention_name>
    <arm_group_label>Nintedanib (BIBF 1120) + BSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age &gt;= 18 years

          -  Signed informed consent

          -  Histologically or cytologically confirmed colorectal adenocarcinoma

          -  Metastatic or locally advanced disease not amenable to curative surgery and/or
             radiotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status = 1

          -  At least one measurable lesion according to Response Evaluation Criteria In Solid
             Tumours (RECIST) version 1.1

          -  Progression on standard therapies or withdrawn from standard treatment due to
             unacceptable toxicity. Previous standard treatment must include all of the following:

          -  - fluoropyrimidine

          -  - oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have
             progressed within 6 months of completion of adjuvant therapy or they must have been
             treated with oxaliplatin for metastatic disease

          -  - irinotecan

          -  - bevacizumab or aflibercept

          -  - cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours

          -  - The remaining standard available therapy as recommended by investigator is best
             supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and
             these agents should be administered before study if available to patient according to
             local standards)

          -  - Life expectancy of at least 12 weeks

          -  - Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT)
             = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver
             metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver
             metastases. Patients with Gilbert syndrome and bilirubin &lt; 2 X ULN and normal AST/ALT
             are eligible

          -  Coagulation parameters: International normalised ratio (INR) &lt; 2 and partial
             prothrombin Time (PTT) = 2xULN

        Exclusion criteria:

          -  Previous treatment with nintedanib

          -  toxicity attributed to previous anticancer therapy that did not resolve to Common
             Terminology Criteria for Adverse Events (CTCAE) grade =1

          -  History of other malignancies in the last 5 years, in particular those that could
             interfere with interpretation of results.

          -  Serious concomitant disease or medical condition affecting compliance with trial
             requirements or which are considered relevant for the evaluation of the efficacy or
             safety of the trial drug,

          -  Significant cardiovascular diseases

          -  History of severe haemorrhagic or thromboembolic event in the past 12 months

          -  Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or
             similar agents requiring therapeutic INR monitoring

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             study drug

          -  Patient with brain metastases that are symptomatic and/or require therapy.

          -  Patients of childbearing potential who are sexually active and unwilling to use a
             highly effective method of contraception

          -  Pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.52.0108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plainville</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.5404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cdad. de Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.5405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cdad. de Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.5401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.5403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.5406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.6102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.6103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.6101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.6104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.6105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.6106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3521 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Luxembourg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København Ø</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 8</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ehime, Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Amagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Yufu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Kitaadachi-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo , Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.5201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jelenia Gora</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Loures</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.0707 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.3407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.8802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.9002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middlesex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.52.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Luxembourg</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>May 8, 2017</results_first_submitted>
  <results_first_submitted_qc>June 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2017</results_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The &quot;completed&quot; patients were on treatment (2 patients on Placebo, 3 patients on Nintedanib) at the data cut-off date 14JUN2016.
The &quot;NOT Completed&quot; patients were off-treatment (380 patients on Placebo, 383 patients on Nintedanib) at the data cut-off date 14JUN2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
        </group>
        <group group_id="P2">
          <title>Nintedanib</title>
          <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="382">Randomised patients.</participants>
                <participants group_id="P2" count="386">Randomised patients.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">On-treatment at analysis cut-off date (14JUN2016).</participants>
                <participants group_id="P2" count="3">On-treatment at analysis cut-off date (14JUN2016).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="380"/>
                <participants group_id="P2" count="383"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease (PD)</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="318"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening/adverse event cancer disease</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Adverse Event (AE)</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to continue trial medication</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomised Set (RS): This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
        </group>
        <group group_id="B2">
          <title>Nintedanib</title>
          <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="382"/>
            <count group_id="B2" value="386"/>
            <count group_id="B3" value="768"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="10.8"/>
                    <measurement group_id="B2" value="61.0" spread="11.3"/>
                    <measurement group_id="B3" value="61.1" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) by Central Review Assessment</title>
        <description>PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan−Meier curve for each treatment arm.</description>
        <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
        <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib</title>
            <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) by Central Review Assessment</title>
          <description>PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan−Meier curve for each treatment arm.</description>
          <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="1.38" upper_limit="1.41"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.45" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hazard ratio, confidence interval and p−value obtained from log−rank test stratified by regorafenib pre−treatment (yes vs no), time from onset metastatic disease until randomisation (less than 24 months vs 24 months or more ) and region.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt;1 favors Nintedanib.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomisation to the time of death from any cause.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan−Meier curve for each treatment arm.</description>
        <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
        <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib</title>
            <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomisation to the time of death from any cause.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan−Meier curve for each treatment arm.</description>
          <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" lower_limit="5.22" upper_limit="6.97"/>
                    <measurement group_id="O2" value="6.44" lower_limit="5.98" upper_limit="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8659</p_value>
            <p_value_desc>Hazard ratio, confidence interval and p−value obtained from log−rank test stratified by regorafenib pre−treatment (yes vs no), time from onset metastatic disease until randomisation (less than 24 months vs 24 months or more ) and region.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Hazard ratio below 1 favors Nintedanib.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment</title>
        <description>Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.</description>
        <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
        <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib</title>
            <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment</title>
          <description>Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.</description>
          <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment</title>
        <description>Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).</description>
        <time_frame>From randomisation until cut-off date 14JUN2016.</time_frame>
        <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib</title>
            <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment</title>
          <description>Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).</description>
          <population>Randomised Set: This patient set included all patients who were randomised to receive treatment, whether treated or not.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="3.68" upper_limit="6.67"/>
                    <measurement group_id="O2" value="25.6" lower_limit="3.65" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Odds ratio and p−value are obtained from logistic regression model adjusted for regorafenib pre−treatment (yes vs no), time from onset metastatic disease until randomization in the trial (less than 24 months vs. 24 months or more) and region.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.00</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
            <estimate_desc>An odds ratio &gt;1 indicates benefit to Nintedanib.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 28 days after last drug administration, up to 22.7 months.</time_frame>
      <desc>patient who was randomised to the Placebo was not treated. Consequently, number of subjects that started is 382 but only 381 reported that includes only treated patients.
patients were randomised to the Nintedanib were not treated. Consequently, number of subjects that started is 386 but only 384 reported that includes only treated patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo soft gelatin capsule matching that of Nintedanib twice daily (b.i.d.) administered orally of 21-day treatment course. If required the dose of placebo, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
        </group>
        <group group_id="E2">
          <title>Nintedanib</title>
          <description>Nintedanib 200 mg twice daily (b.i.d.) administered orally in the form of a soft gelatin capsule of 21-day treatment course. If required the dose of Nintedanib, could be reduced to 150 mg b.i.d. or 100 mg b.i.d. (according to the protocol-defined dose-reduction scheme). No dose increase was allowed after a dose reduction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Fistula of small intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Rectal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Small intestine gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired diaphragmatic eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="309" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="351" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

